Gender differences in non-glycemic responses to improved insulin sensitivity by pioglitazone treatment in patients with type 2 diabetes

Acta Diabetologica

Volumn 51, Issue 2, 2014, Pages 185-192

  Arnetz, Lisa ^a,b   Dorkhan, Mozhgan ^c   Alvarsson, Michael ^a,b   Brismar, Kerstin ^a,b   Ekberg, Neda Rajamand ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cortisol; Gender; Insulin like growth factor; Pioglitazone; Type 2 diabetes

Indexed keywords

ADIPONECTIN; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GROWTH HORMONE; HYDROCORTISONE; INSULIN; INSULIN DERIVATIVE; METFORMIN; PIOGLITAZONE; PROINSULIN; REPAGLINIDE; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C; SULFONYLUREA; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPOQ PROTEIN, HUMAN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; IGFBP1 PROTEIN, HUMAN;

ADULT; ARTICLE; BODY FAT DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; INTERVENTION STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SEX DIFFERENCE; WAIST CIRCUMFERENCE; BLOOD; DIABETES MELLITUS, TYPE 2; INSULIN RESISTANCE; METABOLISM; NONPARAMETRIC TEST; PHYSIOLOGY;

ADIPONECTIN; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROCORTISONE; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; SEX FACTORS; STATISTICS, NONPARAMETRIC; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 84898416576     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-013-0457-y     Document Type: Article

References (43)

1. Stumvoll M, Gerich J (2001) Clinical features of insulin resistance and beta cell dysfunction and the relationship to type 2 diabetes. Clin Lab Med 21:31-51
2. Bjorntorp P, Holm G, Rosmond R (1999) Hypothalamic arousal, insulin resistance and Type 2 diabetes mellitus. Diabet Med 16:373-383
3. Barrett-Connor E (1997) Sex differences in coronary heart disease: why are women so superior? The 1995 Ancel Keys Lecture. Circulation 95:252-264
4. Rajpathak SN, Gunter MJ, Wylie-Rosett J et al (2009) The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab Res Rev 25:3-12
5. Moller N, Vendelbo MH, Kampmann U et al (2009) Growth hormone and protein metabolism. Clin Nutr 28:597-603
6. Baxter RC (1997) Insulin-like growth factor (IGF) binding proteins: the role of serum IGFBPs in regulating IGF availability. Acta paediatr Scand Suppl 372:107-114; discussion 115
7. Young SCJ, Miles MV, Clemmons DR (1992) Determination of the pharmacokinetic profiles of insulin-like growth factor binding proteins-1 and -2 in rats. Endocrinology 131:1867-1873
8. Wheatcroft SB, Kearney MT (2009) IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis. Trends Endocrinol Metab 20:153-162
9. Kotronen A, Lewitt M, Hall K et al (2008) Insulin-like growth factor binding protein 1 as a novel specific marker of hepatic insulin sensitivity. J Clin Endocrinol Metab 93:4867-4872
10. Brismar K, Gutniak M, Povoa G et al (1988) Insulin regulates the 35 kDa IGF binding protein in patients with diabetes mellitus. J Endocrinol Invest 11:599-602
11. Heald AH, Cruickshank JK, Riste LK et al (2001) Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia 44:333-339
12. Ferris HA, Kahn CR (2012) New mechanisms of glucocorticoid-induced insulin resistance: make no bones about it. J Clin Invest 122:3854-3857
13. Wake DJ, Stimson RH, Tan GD et al (2007) Effects of peroxisome proliferator-activated receptor-(alpha) and -(gamma) agonists on 11(beta)-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men. J Clin Endocrinol Metab 92:1848-1856
14. Yki-Jarvinen H (2004) Thiazolidinediones. N Engl J Med 351:1106-1118+1158
15. Heaney AP, Fernando M, Yong WH, Melmed S (2002) Functional PPAR-(gamma) receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 8:1281-1287
16. Dorkhan M, Magnusson M, Frid A et al (2006) Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes. J Intern Med 260:125-133
17. Bang P, Eriksson U, Sara V et al (1991) Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol 124:620-629
18. Hilding A, Brismar K, Degerblad M et al (1995) Altered relation between circulating levels of insulin-like growth factor- binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects. J Clin Endocrinol Metab 80:2646-2652
19. Povoa G, Roovete A, Hall K (1984) Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol 107:563-570
20. Soderberg S, Ahren B, Eliasson M et al (2001) Circulating IGF binding protein-1 is inversely associated with leptin in non-obese men and obese postmenopausal women. Eur J Endocrinol 144:283-290
21. Hellenius MLB, Brismar KE, Berglund BH, De Faire UH (1995) Effects on glucose tolerance, insulin secretion, insulin-like growth factor 1 and its binding protein, IGFBP-1, in a randomized controlled diet and exercise study in healthy, middle-aged men. J Intern Med 238:121-130
22. Sesti G, Sciacqua A, Cardellini M et al (2005) Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance. Diabetes Care 28:120-125
23. Glintborg D, Hermann AP, Hagen C et al (2009) A randomized placebo-controlled study on the effects of pioglitazone on cortisol metabolism in polycystic ovary syndrome. Fertil Steril 91:842-850
24. Weyer C, Funahashi T, Tanaka S et al (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930-1935
25. Sesti G, Federici M, Lauro D et al (2001) Molecular mechanism of insulin resistance in type 2 diabetes mellitus: role of the insulin receptor variant forms. Diabetes Metab Res Rev 17:363-373
26. Federici M, Porzio O, Zucaro L et al (1997) Increased abundance of insulin/IGF-I hybrid receptors in adipose tissue from NIDDM patients. Mol Cell Endocrinol 135:41-47
27. Federici M, Lauro D, D'Adamo M et al (1998) Expression of insulin/IGF-I hybrid receptors is increased in skeletal muscle of patients with chronic primary hyperinsulinemia. Diabetes 47:87-92
28. Andreasson AN, Unden AL, Elofsson S, Brismar K (2012) Leptin and adiponectin: distribution and associations with cardiovascular risk factors in men and women of the general population. Am J Hum Biol 24:595-601
29. Korner A, Wabitsch M, Seidel B et al (2005) Adiponectin expression in humans is dependent on differentiation of adipocytes and down-regulated by humoral serum components of high molecular weight. Biochem Biophys Res Commun 337:540-550
30. Sharma AM, Staels B (2007) Review: peroxisome proliferator-activated receptor (gamma) and adipose tissue - understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 92:386-395
31. Vilarrasa N, Vendrell J, Maravall J et al (2005) Distribution and determinants of adiponectin, resistin and ghrelin in a randomly selected healthy population. Clin Endocrinol 63:329-335
32. Vierhapper H, Nowotny P, Waldhausl W (1998) Sex-specific differences in cortisol production rates in humans. Metabolism 47:974-976
33. Lonn L, Kvist H, Ernest I, Sjostrom L (1994) Changes in body composition and adipose tissue distribution after treatment of women with Cushing's syndrome. Metabolism 43:1517-1522
34. Dutchak PA, Katafuchi T, Bookout AL et al (2012) Fibroblast growth factor-21 regulates PPAR(gamma) activity and the antidiabetic actions of thiazolidinediones. Cell 148:556-567
35. Ambrosi B, Dall'Asta C, Cannavo S et al (2004) Effects of chronic administration of PPAR-(gamma) ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 151:173-178
36. Tsigos C, Chrousos GP (2002) Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res 53:865-871
37. Steiger A (2007) Neurochemical regulation of sleep. J Psychiatr Res 41:537-552
38. Gianotti L, Ramunni J, Lanfranco F et al (2001) Recombinant human IGF-I does not modify the ACTH and cortisol responses to hCRH and hexarelin, a peptidyl GH secretagogue, in humans. J Endocrinol Invest 24:67-71
39. Terzolo M, Reimondo G, Bovio S, Angeli A (2004) Subclinical Cushing's syndrome. Pituitary 7:217-223
40. Conover CA, Divertie GD, Lee PDK (1993) Cortisol increases plasma insulin-like growth factor binding protein-1 in humans. Acta Endocrinol 128:140-143
41. Schwartz AV, Sellmeyer DE, Vittinghoff E et al (2006) Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349-3354
42. Gourlay M, Franceschini N, Sheyn Y (2007) Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures. Clin Rheumatol 26:144-153
43. Heinrichs AAJ, Bortell R, Rahman S et al (1993) Identification of multiple glucocorticoid receptor binding sites in the rat osteocalcin gene promoter. Biochemistry 32:11436-11444